Hao Luo
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Shandong Provincial Natural Science Foundation
Open Date: 2025-01-01
Close Date: 2027-12-01
Articles (13)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Objectives Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is closely associated with dysregulated cell death. This study aims to elucidate the role of the ubiquitin-specific protease 24 (USP24) in ccRCC progression and its molecular mechanisms. Methods Multi-omics data from the TCGA, GEO, and HPA databases were integrated to analyse USP24 expression levels and their clinical significance in ccRCC. The specific mechanism of interaction between USP24 and voltage-dependent anion channel 2 (VDAC2) was validated through co-immunoprecipitation, mass spectrometry analysis, molecular docking, and site-directed mutagenesis. In vitro functional assays – including deubiquitination assays, flow cytometry analysis of apoptosis, and assessment of ferroptosis-related markers – verified USP24’s inhibitory effect on ccRCC. Results USP24 was significantly downregulated in ccRCC tissues and cell lines, with its low expression correlated with poor patient prognosis (hazard ratio [HR]=0.57, p<0.001), suggesting its potential utility as a prognostic indicator. Mechanistic studies revealed that USP24 directly binds VDAC2 and removes its ubiquitinylation at position 277, thereby stabilizing the VDAC2 protein. This stabilizing effect promotes apoptosis and ferroptosis in ccRCC cells, and reactivating this pathway may serve as a viable therapeutic strategy for ccRCC. Single-cell RNA sequencing analysis further confirmed the co-expression of USP24 and VDAC2 in renal tubular epithelial cells. Conclusions This study reveals that the USP24-VDAC2 axis exerts key tumour-suppressive functions by promoting apoptosis and ferroptosis, thereby inhibiting ccRCC progression. Targeting this axis may provide novel therapeutic strategies for ccRCC.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (2)
Hu Lei
Shanghai Jiao Tong University
Yunzhao Wu
Research Associate
University of Cambridge
Make your next move.
Prepare your application
Review drafts before you send them.